1. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy;Rotte;Ann Oncol,2018
2. Current insights into combination therapies with MAPK inhibitors and immune checkpoint blockade;Shin;Int J Mol Sci,2020
3. European Medicines Agency. European Medicines Agency (EMA). New treatment for advanced form of kidney cancer. February 26, 2016. Available from: https://www.ema.europa.eu/en/news/new-treatment-advanced-form-kidney-cancer (Accessed May 2022).
4. Bristol-Myers Squibb. Bristol-Myers Squibb receives FDA approval for Opdivo (nivolumab), the only treatment to deliver significant overall survival in advanced renal cell carcinoma vs. a standard of care, in patients who have received prior anti-angiogenic therapy. November 23, 2015. Available from: https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Receives-FDA-Approval-for-Opdivo-nivolumab-the-Only-Treatment-to-Deliver-Significant-Overall-Survival-in-Advanced-Renal-Cell-Carcinoma-vs-a-Standard-of-Care-in-Patients-Who-Have-Received-Prior-Anti-Angiogenic-Therapy1/default.aspx (Accessed May 2022).
5. Bristol-Myers Squibb Pharma EEIG. EMA. Summary of Product Characteristics: OPDIVO 10 mg/mL concentrate for solution for infusion. Available from: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (Accessed May 2022).